|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADCK5 |
Gene summary for ADCK5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADCK5 | Gene ID | 203054 |
| Gene name | aarF domain containing kinase 5 | |
| Gene Alias | ADCK5 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q3MIX3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 203054 | ADCK5 | LZE4T | Human | Esophagus | ESCC | 3.95e-03 | 1.37e-01 | 0.0811 |
| 203054 | ADCK5 | LZE7T | Human | Esophagus | ESCC | 1.69e-04 | 1.99e-01 | 0.0667 |
| 203054 | ADCK5 | LZE20T | Human | Esophagus | ESCC | 1.11e-02 | 1.61e-01 | 0.0662 |
| 203054 | ADCK5 | LZE22D1 | Human | Esophagus | HGIN | 6.14e-04 | 2.23e-01 | 0.0595 |
| 203054 | ADCK5 | LZE24T | Human | Esophagus | ESCC | 1.06e-08 | 1.91e-01 | 0.0596 |
| 203054 | ADCK5 | LZE21T | Human | Esophagus | ESCC | 3.04e-04 | 2.62e-01 | 0.0655 |
| 203054 | ADCK5 | P1T-E | Human | Esophagus | ESCC | 1.28e-07 | 2.63e-01 | 0.0875 |
| 203054 | ADCK5 | P2T-E | Human | Esophagus | ESCC | 9.44e-07 | 1.32e-01 | 0.1177 |
| 203054 | ADCK5 | P5T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.15e-01 | 0.1327 |
| 203054 | ADCK5 | P8T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.14e-01 | 0.0889 |
| 203054 | ADCK5 | P9T-E | Human | Esophagus | ESCC | 1.67e-03 | 1.07e-01 | 0.1131 |
| 203054 | ADCK5 | P11T-E | Human | Esophagus | ESCC | 1.51e-04 | 2.65e-01 | 0.1426 |
| 203054 | ADCK5 | P12T-E | Human | Esophagus | ESCC | 1.77e-22 | 3.85e-01 | 0.1122 |
| 203054 | ADCK5 | P15T-E | Human | Esophagus | ESCC | 9.67e-06 | 1.66e-01 | 0.1149 |
| 203054 | ADCK5 | P16T-E | Human | Esophagus | ESCC | 1.70e-09 | 1.99e-01 | 0.1153 |
| 203054 | ADCK5 | P17T-E | Human | Esophagus | ESCC | 1.34e-03 | 1.92e-01 | 0.1278 |
| 203054 | ADCK5 | P20T-E | Human | Esophagus | ESCC | 3.93e-07 | 2.18e-01 | 0.1124 |
| 203054 | ADCK5 | P21T-E | Human | Esophagus | ESCC | 2.85e-10 | 2.44e-01 | 0.1617 |
| 203054 | ADCK5 | P22T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.09e-01 | 0.1236 |
| 203054 | ADCK5 | P23T-E | Human | Esophagus | ESCC | 7.76e-16 | 2.76e-01 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADCK5 | SNV | Missense_Mutation | novel | c.487N>C | p.Tyr163His | p.Y163H | Q3MIX3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A3XV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| ADCK5 | SNV | Missense_Mutation | c.334N>A | p.Val112Met | p.V112M | Q3MIX3 | protein_coding | tolerated(0.12) | possibly_damaging(0.849) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| ADCK5 | SNV | Missense_Mutation | c.724A>C | p.Ile242Leu | p.I242L | Q3MIX3 | protein_coding | tolerated(0.33) | benign(0.03) | TCGA-D8-A1Y0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide+methotrexatum+fluorouracillum | SD | |
| ADCK5 | SNV | Missense_Mutation | novel | c.160G>A | p.Ala54Thr | p.A54T | Q3MIX3 | protein_coding | tolerated(1) | benign(0) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ADCK5 | SNV | Missense_Mutation | c.562N>A | p.Glu188Lys | p.E188K | Q3MIX3 | protein_coding | deleterious(0.02) | benign(0.249) | TCGA-EK-A2GZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ADCK5 | SNV | Missense_Mutation | c.550N>A | p.Glu184Lys | p.E184K | Q3MIX3 | protein_coding | tolerated(0.38) | benign(0.046) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ADCK5 | SNV | Missense_Mutation | rs782813437 | c.374C>T | p.Ala125Val | p.A125V | Q3MIX3 | protein_coding | tolerated(0.1) | possibly_damaging(0.747) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| ADCK5 | SNV | Missense_Mutation | c.263G>A | p.Gly88Asp | p.G88D | Q3MIX3 | protein_coding | tolerated(0.21) | benign(0.36) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ADCK5 | SNV | Missense_Mutation | c.29N>C | p.Phe10Ser | p.F10S | Q3MIX3 | protein_coding | tolerated(0.09) | possibly_damaging(0.586) | TCGA-A6-A566-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | PD | |
| ADCK5 | SNV | Missense_Mutation | c.809G>T | p.Gly270Val | p.G270V | Q3MIX3 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |